Yuhan Pharmaceutical Signs $38M API Supply Contract with BridgeBio for Cardiomyopathy Treatment

Yuhan Pharmaceutical (000100) announced on May 6 through DART disclosure that it has signed a contract to supply active pharmaceutical ingredients (API) for a cardiomyopathy therapy to U.S. rare disease biotech BridgeBio Pharma, Inc. (BBIO) at approximately 55.99 billion won ($38.1 million). This represents 2.56% of Yuhan Pharmaceutical's 2025 consolidated net revenue of approximately 218.66 billion won.

Why Yuhan Pharmaceutical—API Manufacturing Capability and BridgeBio's Cardiomyopathy Pipeline

BridgeBio Pharma is a Nasdaq-listed biotech specializing in rare and genetic diseases. The company received FDA approval for its transthyretin amyloid cardiomyopathy (ATTR-CM) treatment 'Attruby' in 2024 and has entered the commercialization phase. Cardiomyopathy, a condition where heart muscle becomes stiff or thickened, remains a rare disease area with limited treatment options. Under this contract, Yuhan Pharmaceutical will manufacture and supply the API—a critical raw material for this therapy—representing a B2B manufacturing-based supply agreement rather than simple finished product distribution.

The contract period runs from May 5, 2026 to March 1, 2028, approximately 22 months. There are no upfront payments or advances; payment terms are NET +30 days from invoice. According to the disclosure, the sales and supply region remains undetermined, with the contract date based on purchase order receipt.

Q1 2026 Results and H2 Momentum

Yuhan Pharmaceutical's Q1 2026 revenue reached 509.6 billion won, up approximately 8% year-over-year, while operating profit grew 2.1% to 8.8 billion won, falling short of market consensus. Industry reports noted that H2 new drug momentum remains solid, with Reclaza (lung cancer treatment) global revenue expansion cited as a key variable. This BridgeBio API supply contract demonstrates that manufacturing-based revenue streams are diversifying beyond Reclaza.

Key Biotech and Pharma Sector Stocks

• Hanmi Pharmaceutical (128940): Large-cap pharmaceutical with competitive global technology export capabilities based on proprietary new drug pipelines; a representative domestic player alongside Yuhan in API and finished product manufacturing.
• Samsung Biologics (207940): Ranked among the top global contract manufacturers of biologics (CMO/CDMO); benefits directly from rising API manufacturing demand.
• Celltrion (068270): Large biotech with in-house biosimilar development and production capabilities, advancing into global rare disease markets.
• SK Biopharm (326030): Specialized biotech focused on rare and CNS disorder drug development with FDA-approved products.
• Jinwon Life Science (051630): Mid-cap biotech manufacturer with nucleic acid and protein-based pharmaceutical production capabilities.

This contract represents a significant diversification of Yuhan Pharmaceutical's business model, transitioning from finished drug distribution to serving as an API manufacturer in global pharmaceutical supply chains. While industry analysts view H2 new drug momentum as supportive, actual revenue recognition from this API contract may be distributed across 2026–2028 based on delivery schedules. Given the absence of upfront payments or advances, revenue timing and magnitude depend on actual delivery progress. Investors should remain cautious of volatility in rapidly rising small-cap stocks.

This article was auto-generated based on the original DART disclosure and external reporting, intended for rapid dissemination of key data following announcement. We recommend reviewing the official company disclosure before making trading decisions. Disclosure link: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260506800401